Back to results
US 9,849,159 B2Granted
Eluting matrix and uses thereof
AssigneeThe General Hospital Corporation
InventorsMark C. Poznansky, Tao Chen
Life of this patent
Estimating the term…
Abstract
CXCL12 polypeptide eluting matrices encapsulating at least one cell are described for use in the treatment of autoimmune disorders.
Claims23
An eluting matrix suitable for implantation into a mammal, said matrix comprising at least one protein expressing-cell,
- wherein said cell is encapsulated in a CXCL12-eluting porous polymeric-matrix which is permeable to the protein, and further
- wherein the elution rate of CXCL12 from the matrix is from about 1 ng/mL/hr to about 3 ng/mL/hr so as to repel effector T-cells surrounding said matrix for a period of at least one month after implantation.
An eluting matrix suitable for implantation into a mammal, said matrix comprising at least one xenogenic islet cell capable of expressing insulin,
- wherein said cell is encapsulated in a CXCL12-eluting porous alginate matrix having a thickness of from about 200 microns to about 500 microns which is permeable to the insulin, and further
- wherein the elution rate of CXCL12 from the matrix is from about 1 ng/mL/hr to about 3 ng/mL/hr so as to repel effector T-cells surrounding said matrix which is maintained for a period of at least one month after implantation.
Dependencies are inferred from the claim text.